The Labs Your Doctor Didn't Run (Pre-Protocol Bloodwork Blueprint)

Your doctor checks total testosterone, tells you the number is normal, and sends you home. And that interaction, as common as it is, misses almost everything that actually matters.

Here is why that single number fails you, and what a complete picture actually looks like.

Testosterone does not travel through your blood freely. Most of it is bound to proteins, primarily something called SHBG, which stands for sex hormone binding globulin, and what it does is lock testosterone into a form your cells cannot use. Only the fraction that is unbound, what labs call free testosterone, can actually enter a cell and do what testosterone is supposed to do.

So when your doctor reports a total testosterone of 600 ng/dL and calls it fine, that number includes both the usable and the locked-up portion together. A man with 400 ng/dL total testosterone but low SHBG may have more biologically active hormone than the man at 600 with high SHBG. The number on the report tells you how much testosterone is in the blood. It does not tell you how much your body can actually use.

That is why free testosterone and SHBG belong on every baseline panel.

But knowing your levels are low does not tell you where the breakdown is happening. The system works like this: the brain sends a signal down to the testes, the testes respond by producing testosterone, and the testosterone feeds back to the brain to regulate how much signal to send. Two hormones manage the signaling side, something called LH (luteinizing hormone) and FSH (follicle stimulating hormone), both released from the pituitary gland in the brain.

If testosterone is low and LH is also low, the problem is upstream. The brain is not sending the signal. If testosterone is low but LH is high, the testes are receiving the signal and not responding to it. These are two completely different physiological situations and they lead to completely different treatment decisions. Running total testosterone without LH and FSH is like knowing a car will not start without checking whether the problem is the ignition or the engine.

The rest of the hormonal picture rounds out the map. Estradiol, the primary estrogen in men, is produced when testosterone converts via an enzyme called aromatase, and measuring it with a sensitive assay matters because the standard estradiol test used for women is not accurate enough for male ranges. Prolactin, DHEA sulfate, progesterone, and cortisol each give you information about different axes of the endocrine system that interact with testosterone and affect how a man feels even when testosterone itself looks adequate.

The metabolic panel is where the standard of care falls furthest short.

Most doctors run a basic metabolic panel that includes blood glucose. If your glucose is in range, the assumption is your metabolism is fine. But glucose is a lagging indicator. By the time fasting glucose is elevated, something called insulin resistance has usually been developing for years, where your cells have stopped responding efficiently to insulin and your pancreas has been compensating by producing more of it.

Fasting insulin captures that compensation directly. A person can have perfectly normal fasting glucose while fasting insulin is already elevated, which tells you the pancreas is working overtime to maintain that normal reading. Hemoglobin A1c, which reflects average blood sugar over roughly three months, adds the time dimension that a single glucose snapshot cannot. Together, these three markers give you a real picture of metabolic function rather than a snapshot of one moment.

This matters for hormone optimization specifically because insulin resistance and low testosterone are bidirectionally connected. Metabolic dysfunction suppresses hormonal function, and low testosterone worsens metabolic markers. You cannot address one without understanding the other.

Cardiovascular baseline follows the same logic of looking past surface numbers.

A standard lipid panel gives you total cholesterol, LDL, HDL, and triglycerides. Those numbers describe how much lipid is in your blood. They do not describe how many particles are carrying it, and particle count is what actually drives plaque formation in artery walls. Something called apolipoprotein B, or ApoB, measures the total number of atherogenic particles directly. Two people can have identical LDL cholesterol readings and have meaningfully different cardiovascular risk depending on their particle count.

High sensitivity C-reactive protein, or hs-CRP, adds the inflammation dimension. Atherosclerosis is not purely a lipid accumulation problem. It is an inflammatory process, and hs-CRP reflects systemic inflammation that predicts cardiovascular events independently of lipid levels.

The safety markers round out the panel in a way that matters specifically because of what testosterone does to the body.

Testosterone stimulates red blood cell production. That is a known physiological effect. When hematocrit, which is the percentage of your blood volume made up of red blood cells, rises too high, blood becomes more viscous and the risk of clotting events increases. Research published in the Journal of Urology in 2022 found that men on testosterone therapy with hematocrit at or above 52 percent had a 35 percent higher risk of major cardiovascular events and venous thromboembolism compared to those below that threshold. You need that baseline before starting, and you need to monitor it throughout.

A full thyroid panel, TSH with free T3 and free T4, matters because hypothyroidism produces a symptom profile that overlaps almost entirely with low testosterone. Fatigue, low libido, cognitive fog, weight gain. Without thyroid markers, you cannot distinguish between the two or account for both.

IGF-1 establishes your baseline growth hormone activity before any peptide protocols are introduced. Without that baseline number, you have no way to measure whether an intervention is actually working.

PSA and a CBC with differential complete the picture by giving you prostate baseline and immune function data before anything is changed.

The reason this panel matters is not bureaucratic. It is diagnostic. A protocol built without this information is not optimization. It is guesswork applied to a system you have not actually measured. And the difference between those two things is the difference between feeling better and understanding why you feel better, which is the only position from which you can make informed decisions about what comes next.

---

References

1. Bhasin S et al. Testosterone Therapy in Men With Hypogonadism. JCEM. 2018 — Endocrine Society guideline: diagnosis requires two fasting morning total T measurements, distinguish primary vs secondary via LH/FSH
2. Mulhall JP et al. Evaluation and Management of Testosterone Deficiency. AUA Guideline. J Urology. 2018 — Total T below 300 ng/dL threshold, recommend LH in all men with low T
3. Travison TG et al. Harmonized Reference Ranges for Circulating Testosterone Levels. JCEM. 2017 — 9,054 men, harmonized range 264-916 ng/dL
4. Ory J et al. Secondary Polycythemia in Men Receiving Testosterone Therapy. J Urology. 2022 — Hematocrit >=52% on TRT = 35% higher MACE/VTE risk (OR 1.35)
5. Rosner W et al. Toward Excellence in Testosterone Testing. JCEM. 2013 — Sensitive LC-MS/MS required for accurate male estradiol

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness